Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Donna Lamb is using her medical education perspective in her latest leadership role, from her job as a critical care nurse to working with doctors to connect nurses who are checking patients on the job during the outbreak.
Read Full NewsNew findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.
A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.
FDA Approves First Dual-Agent Eye Drop for Near Vision Loss
1.
How AI will transform mental health support for patients with breast cancer
2.
Alarm Over Pharma-China Link; Taking Screening to the People; Agriculture and Cancer
3.
The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.
4.
Recent research suggests that vitamin supplements may increase the risk of developing cancer.
5.
Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer
1.
Unmasking the Hidden Symptoms of Ovarian Cancer
2.
Managing Hematoma: A Guide to Prevention and Treatment
3.
Navigating the Complexities of Esophageal Cancer Staging
4.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
5.
The Digital Biopsy: How Artificial Intelligence is Redefining Cancer Pathology?
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
5.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge